Cited by 423Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsSirtuins and Resveratrol in Medicine

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index; none of the 106 sources its claims cite is checked for support yet.

Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity

Open access

Abstract

Cellular senescence is a fundamental aging mechanism that has been implicated in many age-related diseases and is a significant cause of tissue dysfunction. Accumulation of senescent cells occurs during aging and is also seen in the context of obesity and diabetes. Senescent cells may play a role in type 2 diabetes pathogenesis through direct impact on pancreatic β-cell function, senescence-associated secretory phenotype (SASP)-mediated tissue damage, and involvement in adipose tissue dysfunction. In turn, metabolic and signaling changes seen in diabetes, such as high circulating glucose, altered lipid metabolism, and growth hormone axis perturbations, can promote senescent cell formation. Thus, senescent cells might be part of a pathogenic loop in diabetes, as both a cause and consequence of metabolic changes and tissue damage. Therapeutic targeting of a basic aging mechanism such as cellular senescence may have a large impact on disease pathogenesis and could be more effective in preventing the progression of diabetes complications than currently available therapies that have limited impact on already existing tissue damage. Therefore, senescent cells and the SASP represent significant opportunities for advancement in the prevention and treatment of type 2 diabetes and its complications.

Overview

Integrity signals

Registry

Crossref · 10.2337/db14-1820

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 106 cited sources checked · 0 supported · 0 flagged

Show all 68 claims

  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 13
35 of 35
  • The paper relies on this without support.

    Current therapies for type 2 diabetes have limited efficacy in slowing disease progression and complications.

    “Despite increased understanding of the pathogenesis of diabetes and its comorbidities, current therapies have limited efficacy with respect to its progression and complications.”
  • The paper relies on this without support.

    Metformin improves diabetes, its complications and the metabolic syndrome.

    “Metformin alleviates diabetes, diabetes complications, and the metabolic syndrome.”
  • The paper relies on this without support.

    The composition of the senescence-associated secretory phenotype differs by cell type, tissue type and organism, and its factors have several roles in inflammation, immunity and normal physiology.

    “This issue is complicated by cell-type, tissue-type, and organismal differences in the composition of the SASP, as well as the multiple effects that SASP factors can play in inflammation, immunity, and normal physiology.”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 94 references

Cited by

Sorted by citations

Items 401–419 of 419

Metadata

Authors
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L.
Affiliations
  • Mayo Clinic (US)
  • Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN
Corresponding author
Kirkland, James L.
Venue
Diabetes
Published
2015-06-17
Volume
64
Issue
7
Pages
2289-2298
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W1908141864
Cited by
423
References
94
Citations by year
2026: 33 · 2025: 32 · 2024: 47 · 2023: 33 · 2022: 62 · 2021: 47 · 2020: 48 · 2019: 41 · 2018: 29 · 2017: 27 · 2016: 18 · 2015: 4
FWCI
3.20
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Noaber Foundation
  • Glenn Foundation for Medical Research
  • National Institute on Aging (AG044396, AG046061)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
cellular senescence, type 2 diabetes, senescence-associated secretory phenotype, beta-cell dysfunction, adipose tissue dysfunction, aging, obesity, growth hormone axis, diabetes complications, senolytics
MeSH terms
Adipose Tissue, Animals, Ceramides, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Insulin-Like Growth Factor I, Cellular Senescence, Insulin-Like Growth Factor Binding Protein 3, Insulin-Secreting Cells, Cellular Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review